Risankizumab
Based on 1 Customer Validation
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.37%
- CAS 番号: 1612838-76-2
- 分子量:145.92 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 (L234A/L235A) kappa
Human
|
IL-23 <10 pM (Kd) |
Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds <10 pM[3].
Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dosage
-
Result:Significantly inhibited IL23-induced ear swelling and cytokine production.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:1.0 mg/kg
-
Administration:i.v. or s.c.
-
Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys[1].
IV (1 mg/kg) SC (1 mg/kg) AUCinf (μg·day/mL) 202 ± 33.5 142 ± 33.3 CL (mL/day/kg) 5.18 ± 0.8 / Vd, ss (mL/kg) 88.3 ± 3.12 / t1/2 (h) 12.2 ± 2.28/ 9.15 ± 1.87 Cmax (μg/mL) / 10.1 ± 3.14 Tmax (day) / 2.11 ± 1.84 F (%) / 70.4 ± 16.5
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling IL-23A (red) with Risankizumab (anti-IL-23A) (HY-P99248). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1612838-76-2
-
性状 Liquid
-
分子量 145.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Risankizumab]
-
別名
Risankizumab rzaa; BI 655066; ABBV-066
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)